Quick Facts About: Nivolumab

Medically Reviewed by Vishal Shah, PharmD, MBA
Written by Samantha PhuaFeb 13, 20244 min read
Cancer Treatment Drugs

Source: Shutterstock.

Alternative names

Opdivo

FDA approved?

Yes, in 2015.

Used to treat

Metastatic colorectal cancer

Administration and dosage

Nivolumab is administered intravenously.

Nivolumab is administered in doses of 240 mg or 3 mg/kg with ipilimumab via infusion over 60 minutes at two-week intervals. This continues until disease progression or unacceptable toxicity levels are reached.

Nivolumab may be administered as monotherapy or in combination with ipilimumab to treat metastatic colorectal cancer with high microsatellite instability.

Contraindications and precautions

Special precaution is required for the following cases:

  • Patients with existing or a history of brain metastases
  • Patients with auto-immune disease or under systemic immunosuppression
  • Patients with severely impaired liver function
  • Pregnancy and lactation
  • Presence of other forms of carcinoma

Side effects

Patients who experience the following severe side effects should seek immediate medical attention.

  • Darkening of skin, severe tiredness, unintentional weight loss, salt craving, lightheadedness or fainting
  • Rashes with skin peeling or blisters
  • Yellowing of the skin or eyes
  • Severe diarrhea, blood in stool
  • Severe headache, frequent urination
  • Pain or burning sensation when urinating, blood in urine
  • Swelling in your neck, being sensitive to heat or cold
  • Unusual bleeding or bruising
  • Mouth sores, frequent and persistent sore throat with fever

Type of treatment

Nivolumab is a monoclonal antibody.

Treatment mechanism

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody which binds to immunoregulatory protein programmed death-1 (PD-1) receptors.

PD-1 ligands are overexpressed on the surface of tumor cells and lead to the activation of PD-1, which suppresses cytotoxic T-cell activity. Nivolumab blocks the interaction between PD-1 and its ligands and enhances the immune response to tumor cells.

Share this article:

This article has been medically reviewed and fact-checked to ensure our content is informed by the latest research in cancer, global and nationwide guidelines and clinical practice.

Click here for more information.